Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TRANSMEDICS GROUP, INC.

(TMDX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/14/2021 06/15/2021 06/16/2021 06/17/2021 06/18/2021 Date
28.61(c) 28.51(c) 29.57(c) 29.98(c) 29.78(c) Last
258 361 220 915 303 712 409 632 884 164 Volume
+1.06% -0.35% +3.72% +1.39% -0.67% Change
More quotes
Financials (USD)
Sales 2021 38,4 M - -
Net income 2021 -31,4 M - -
Net cash position 2021 64,9 M - -
P/E ratio 2021 -26,4x
Yield 2021 -
Sales 2022 83,3 M - -
Net income 2022 -17,5 M - -
Net cash position 2022 48,1 M - -
P/E ratio 2022 -48,9x
Yield 2022 -
Capitalization 823 M 823 M -
EV / Sales 2021 19,7x
EV / Sales 2022 9,30x
Nbr of Employees 110
Free-Float 93,0%
More Financials
Company
Transmedics group, Inc. is a commercial-stage medical technology company. It is focused on developing organ transplant therapy for end-stage organ failure patients across multiple disease states. The Company has designed and developed organ care system (OCS) a portable organ perfusion, optimization and monitoring system that utilizes customized technology to replicate near-physiologic conditions for donor organs... 
More about the company
Ratings of TransMedics Group, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about TRANSMEDICS GROUP, INC.
06/10TRANSMEDICS'  : OCS Liver System for Organ Transplants to Be Reviewed by FDA Adv..
MT
06/10TRANSMEDICS  : Announces Scheduling of OCS Liver FDA Advisory Committee Meeting
PR
05/28TRANSMEDICS GROUP, INC.  : Submission of Matters to a Vote of Security Holders (..
AQ
05/07TRANSMEDICS  : Management's Discussion and Analysis of Financial Condition and R..
AQ
05/05TRANSMEDICS  : Oppenheimer Adjusts TransMedics Group PT to $49 From $60, Maintai..
MT
05/05TRANSMEDICS  : Morgan Stanley Adjusts TransMedics Group PT to $35 From $38, Main..
MT
05/04TRANSMEDICS : Q1 Earnings Snapshot
AQ
05/04TRANSMEDICS GROUP, INC.  : Results of Operations and Financial Condition, Financ..
AQ
05/04TRANSMEDICS  : Earnings Flash (TMDX) TRANSMEDICS GROUP Posts Q1 Revenue $7.1M, v..
MT
05/04TRANSMEDICS  : Reports First Quarter 2021 Financial Results
PR
04/20TRANSMEDICS  : to Report First Quarter 2021 Financial Results on May 4, 2021
PR
04/07TRANSMEDICS  : Oppenheimer Adjusts TransMedics Group PT to $60 From $44 on Posit..
MT
04/07SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Wednesday
MT
04/07SECTOR UPDATE : Health Care
MT
04/07TRANSMEDICS GROUP, INC.  : Regulation FD Disclosure, Financial Statements and Ex..
AQ
More news
News in other languages on TRANSMEDICS GROUP, INC.

- No features available -

More news
Analyst Recommendations on TRANSMEDICS GROUP, INC.
More recommendations
Chart TRANSMEDICS GROUP, INC.
Duration : Period :
TransMedics Group, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TRANSMEDICS GROUP, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 48,20 $
Last Close Price 29,78 $
Spread / Highest target 165%
Spread / Average Target 61,9%
Spread / Lowest Target -2,62%
EPS Revisions
Managers and Directors
NameTitle
Waleed H. Hassanein President, Chief Executive Officer & Director
Stephen Gordon Chief Financial Officer, Secretary & Treasurer
James R. Tobin Chairman
Phillip Camp Chief Medical Officer
John Sullivan Vice President-Quality & Engineering
Sector and Competitors